The University of Southampton
University of Southampton Institutional Repository

Efficacy/safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial

Record type: Article

Increased tumour necrosis factor (TNF)-? levels have been observed in bronchial biopsies and induced sputum from subjects with severe asthma. We investigated etanercept (ETN) as a therapeutic option for treating moderate-to-severe persistent asthma. In this 12-week, randomised, double-blind, placebo-controlled, phase 2 trial, subjects (n=132) with moderate-to-severe persistent asthma received subcutaneous injections of ETN 25 mg or placebo twice weekly and were evaluated at baseline and at weeks 2, 4, 8, and 12. The primary end-point was the change from baseline to week 12 in pre-bronchodilator forced expiratory volume in 1 second (FEV1) % predicted. Secondary end-points included morning peak expiratory flow; FEV1 % predicted; Asthma Control Questionnaire; asthma exacerbations; PC20 assessed by methacholine challenge; and the Asthma Quality of Life Questionnaire. No significant differences were observed between ETN and placebo for any of the efficacy end-points. ETN treatment was well tolerated, with no unexpected safety findings observed during the study. Clinical efficacy of ETN was not shown in subjects with moderate-to-severe persistent asthma over 12 weeks. However, ETN treatment was a well-tolerated therapy. Studies in specific subsets of patients with asthma with longer-term follow-up may be needed to fully evaluate the clinical efficacy of ETN in this population.

Full text not available from this repository.

Citation

Holgate, S.T., Noonan, M., Chanez, P., Busse, W., Dupont, L., Pavord, I., Hakulinen, A., Paolozzi, L., Wajdula, J., Zang, C., Nelson, H. and Raible, D. (2011) Efficacy/safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial European Respiratory Journal, 37, (6), pp. 1352-1359. (doi:10.1183/09031936.00063510). (PMID:21109557).

More information

e-pub ahead of print date: 25 November 2010
Published date: June 2011
Keywords: asthma, etanercept, forced expiratory volume
Organisations: Infection Inflammation & Immunity

Identifiers

Local EPrints ID: 183177
URI: http://eprints.soton.ac.uk/id/eprint/183177
ISSN: 0903-1936
PURE UUID: 2e65783b-b5e7-4988-bca0-893d2d50a86c

Catalogue record

Date deposited: 28 Apr 2011 14:43
Last modified: 18 Jul 2017 11:55

Export record

Altmetrics

Contributors

Author: S.T. Holgate
Author: M. Noonan
Author: P. Chanez
Author: W. Busse
Author: L. Dupont
Author: I. Pavord
Author: A. Hakulinen
Author: L. Paolozzi
Author: J. Wajdula
Author: C. Zang
Author: H. Nelson
Author: D. Raible

University divisions


Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×